US · KRYS · BIOTECHNOLOGY
Krystal Biotech, Inc. (KRYS) intrinsic value and stock valuation
$308.89as of 2026-11-21 · Mkt cap 9.6B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Krystal Biotech, Inc. DCF and intrinsic value
InvestorsCraft values KRYS with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from KRYS’s statements →
Krystal Biotech, Inc. Graham Number
Graham Number: $81.91d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2016–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Arrowhead Pharmaceuticals, Inc. (ARWR) $41.37
- Protagonist Therapeutics, Inc. (PTGX) $121.40
- Alkermes plc (ALKS) $44.94
- Vaxcyte, Inc. (PCVX) $55.39
- TG Therapeutics, Inc. (TGTX) $63.34
- Teleflex Incorporated (TFX) $161.58
- PTC Therapeutics, Inc. (PTCT) $56.42
- CRISPR Therapeutics AG (CRSP) $39.10
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $389.1M | $290.5M | $50.7M | $0.00 | $0.00 |
| Operating income | $161.3M | $65.7M | -$-109.73M | -$-145.2M | -$-68.28M |
| Net income | $204.8M | $89.2M | $10.9M | -$-139.97M | -$-69.57M |
| EPSd | $6.84M | $3M | $393.9K | -$-5.49M | -$-3.13M |
| Operating cash flow | $200.9M | $123.4M | -$-88.8M | -$-100.57M | -$-47.94M |
| Capital expenditure | -$-11.95M | -$-4.24M | -$-11.8M | -$-52.98M | -$-68.34M |
| Free cash flow | $188.9M | $119.2M | -$-100.6M | -$-153.55M | -$-116.27M |
| Total assets | $1.33B | $1.06B | $818.4M | $558.5M | $626.3M |
| Total debt | $9.34M | $7.26M | $8.09M | $8.93M | $8.02M |
| Net debt | -$-486.96M | -$-337.6M | -$-350.23M | -$-152.97M | -$-333.22M |
| Total equity | $1.22B | $946.4M | $778.6M | $522.2M | $593.6M |
| Cash and short-term investments | $827.8M | $597.5M | $532.2M | $379.2M | $438.1M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $389.1M | $290.5M | $50.7M | $0.00 | $0.00 |
| Cost of revenue | $28.8M | $20.1M | $3.09M | $0.00 | $0.00 |
| Gross profit | $360.4M | $270.5M | $47.6M | $0.00 | $0.00 |
| Research and development expenses | $58.1M | $53.6M | $46.4M | $42.5M | $27.9M |
| Selling, general and administrative expenses | $146.7M | $113.7M | $98.4M | $77.7M | $40.4M |
| Other expenses | -$-5.72M | $37.5M | $12.5M | $25M | $0.00 |
| Operating expenses | $199.1M | $204.8M | $157.3M | $145.2M | $68.3M |
| Cost and expenses | $227.8M | $224.8M | $160.4M | $145.2M | $68.3M |
| Interest income | $28.2M | $29.7M | $22.6M | $5.22M | $200K |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $1.49M |
| Depreciation and amortization | $6.55M | $6.71M | $5.91M | $3.38M | $1.85M |
| Ebitda | $196M | $109.9M | -$-91.32M | -$-116.81M | -$-66.23M |
| Operating income | $161.3M | $65.7M | -$-109.73M | -$-145.2M | -$-68.28M |
| Total other income/expenses, net | $28.2M | $29.7M | $122.6M | $5.22M | -$-1.29M |
| Income before tax | $189.5M | $95.4M | $12.9M | -$-139.97M | -$-69.57M |
| Income tax expense | -$-15.36M | $6.2M | $1.97M | $0.00 | $0.00 |
| Net income | $204.8M | $89.2M | $10.9M | -$-139.97M | -$-69.57M |
| Weighted average shares outstanding | $28.9M | $28.6M | $27.2M | $25.5M | $22.2M |
| Weighted average diluted shares outstanding | $30M | $29.7M | $27.8M | $25.5M | $22.2M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $827.8M | $597.5M | $532.2M | $379.2M | $438.1M |
| Net receivables | $127.4M | $104.8M | $42M | $0.00 | $0.00 |
| Inventory | $40.5M | $26.5M | $6.99M | $0.00 | $0.00 |
| Total current assets | $1.02B | $742M | $587.9M | $383.8M | $442.3M |
| Property, plant and equipment, net | $158M | $161.5M | $168.2M | $169.7M | $119.6M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $128.1M | $152.1M | $62M | $4.62M | $64.4M |
| Total non-current assets | $309.2M | $313.8M | $230.5M | $174.7M | $184M |
| Total assets | $1.33B | $1.06B | $818.4M | $558.5M | $626.3M |
| Accounts payable | $3.24M | $4.99M | $1.85M | $3.98M | $8.4M |
| Short-term debt | $1.77M | $1.22M | $1.47M | $1.56M | $1.04M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $102.9M | $102M | $33.1M | $28.9M | $25.7M |
| Long-term debt | $7.57M | $6.04M | $6.62M | $7.37M | $6.98M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $11.3M | $7.46M | $6.62M | $7.37M | $6.98M |
| Capital lease obligations | $9.34M | $7.26M | $8.09M | $8.93M | $8.02M |
| Total liabilities | $114.2M | $109.5M | $39.7M | $36.2M | $32.7M |
| Common stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Retained earnings | $24.2M | -$-180.67M | -$-269.83M | -$-280.76M | -$-140.78M |
| Accumulated other comprehensive income (loss) | $1.14M | -$-190K | $640K | -$-730K | -$-160K |
| Total equity | $1.22B | $946.4M | $778.6M | $522.2M | $593.6M |
| Total investments | $459.6M | $404.8M | $235.8M | $221.9M | $161.2M |
| Total debt | $9.34M | $7.26M | $8.09M | $8.93M | $8.02M |
| Net debt | -$-486.96M | -$-337.6M | -$-350.23M | -$-152.97M | -$-333.22M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $204.8M | $89.2M | $10.9M | -$-139.97M | -$-69.57M |
| Depreciation and amortization | $6.55M | $6.71M | $5.01M | $4.05M | $2.77M |
| Stock-based compensation | $54.5M | $49.1M | $39.9M | $33.2M | $15.3M |
| Change in working capital | -$-36.42M | -$-14.46M | -$-37.88M | $2.81M | $2.05M |
| Accounts receivable | -$-22.12M | -$-62.71M | -$-42.04M | $0.00 | $0.00 |
| Inventory | -$-6.29M | -$-11.91M | -$-4.47M | $0.00 | $0.00 |
| Accounts payable | $830K | $1.01M | -$-100K | -$-1.25M | $710K |
| Net cash provided by operating activities | $200.9M | $123.4M | -$-88.8M | -$-100.57M | -$-47.94M |
| Investments in property, plant and equipment | -$-11.95M | -$-4.24M | -$-11.8M | -$-52.98M | -$-68.34M |
| Acquisitions, net | $430K | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-58.42M | -$-163.44M | $82.6M | -$-114.08M | -$-226.77M |
| Common stock issued | $22.7M | $32.4M | $203.5M | $36M | $355.6M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $8.71M | $27M | $202.8M | $35.4M | $347.7M |
| Net change in cash | $151.4M | -$-13.46M | $196.4M | -$-179.35M | $73M |
| Cash at end of period | $496.3M | $344.9M | $358.3M | $161.9M | $341.3M |
| Operating cash flow | $200.9M | $123.4M | -$-88.8M | -$-100.57M | -$-47.94M |
| Capital expenditure | -$-11.95M | -$-4.24M | -$-11.8M | -$-52.98M | -$-68.34M |
| Free cash flow | $188.9M | $119.2M | -$-100.6M | -$-153.55M | -$-116.27M |
Line items
Line items
Line items
About Krystal Biotech, Inc.
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
- CEO
- Krish S. Krishnan
- Employees
- 295
- Beta
- 0.50
Explore
Frequently asked questions
What is the intrinsic value of Krystal Biotech, Inc. (KRYS)?
Krystal Biotech, Inc. (KRYS) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is KRYS undervalued?
KRYS trades at a price of $308.89 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.